Navigation Links
Patients Often Kept in Dark About 'Off-Label' Drug Use: Study
Date:8/8/2012

WEDNESDAY, Aug. 8 (HealthDay News) -- Many patients who are being treated with "off-label" drugs are unaware that the medications they have been prescribed by their doctor aren't being used in ways that would meet U.S. Food and Drug Administration approval, research shows.

Off-label drug use is a term used to describe when a medication is prescribed using a dosage, form of dosage, or for a purpose that hasn't yet been approved by the FDA, the researchers explained in the report published online Aug. 6 in the Mayo Clinic Proceedings.

"Since the U.S. Food and Drug Administration does not regulate the practice of medicine, off-label drug use has become very common," study lead author Dr. Christopher Wittich, an internal medicine physician at the Mayo Clinic in Rochester, Minn., said in a clinic news release. "Health care providers and patients should educate themselves about off-label drugs to weigh the risks and benefits before a physician prescribes one or a patient takes one."

A 2006 report revealed that among the most common medications, roughly one in five prescriptions was for an off-label use, the researchers pointed out. For example, some antidepressants are considered a primary treatment for neuropathic pain, although this use is not FDA-approved.

Morphine, as well as many inhaled bronchodilators, antimicrobials, anticonvulsants and proton pump inhibitors are also prescribed for children without being FDA-approved for use in kids. Previous research has shown that about 79 percent of kids were taking at least one off-label medication when they were discharged from a children's hospital, the study authors noted in the release.

Because doctors are not required to disclose the off-label use of a drug, and are also not liable for off-label drug use, patients are commonly not told that they are taking a drug in a way that is not FDA-approved, the researchers pointed out.

Drug makers, however, are not allowed to promote off-label uses of their drugs. Doing so can result in hefty fines, the study authors explained. For example, GlaxoSmithKline recently agreed to pay a record $3 billion to settle a case involving alleged off-label drug-use marketing, and Merck Sharp & Dohme was fined $322 million for allegedly promoting the painkiller Vioxx for an off-label use.

But, Wittich and colleagues noted, drug companies are allowed to respond to questions from health care providers and distribute peer-reviewed publications about off-label drug use.

The high costs and lengthy process of obtaining FDA approval may deter drug companies from seeking approval for a new drug indication, the researchers suggested.

More information

The American Cancer Society has more about off-label drug use.

-- Mary Elizabeth Dallas

SOURCE: Mayo Clinic, news release, Aug. 6, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Underinsured Heart Disease Patients Die Sooner, Study Finds
2. Doctors often dont disclose all possible risks to patients before treatment
3. Patients want more risks disclosed before treatment
4. No difference in death rates among patients exposed to common rheumatoid arthritis drugs
5. Weekends More Fatal for Older Patients With Head Injury: Study
6. Coach could be key in helping stroke patients
7. Minority Patients at Higher Risk of Having Ambulances Diverted
8. Tourette Patients Benefit From Behavioral Therapy: Study
9. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
10. Off-label drug use common, but patients may not know theyre taking them, Mayo finds
11. Trauma Patients at Higher Risk of Dying of Hypothermia: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patients Often Kept in Dark About 'Off-Label' Drug Use: Study
(Date:8/23/2017)... , ... August 23, 2017 , ... ... to support long-term strategic growth plans, announcing the hiring of Kevin Keelan as ... technology consultant and seasoned sales manager, Keelan will be working with Virsys12 senior ...
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... accessible luxurious collection of unique masks and serums that perfectly fuse the beauty ... care advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... ... ... Glass is new to the Texas market, but is proudly managed by widely recognized All ... models, in Grand Prairie, TX, located in the center of the DFW Metroplex, the fourth ... for the past 40 years with 32 convenient locations in Texas, Nevada and California resulting ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... “Covert Awakening” is the creation of published author, Julianne Hale, a consultant ... as a policy and counter-terrorism expert focusing on the Near East region. ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)...   Second-quarter 2017 revenues of ... share from continuing operations ... to $110 million Second-quarter ... million Second-quarter 2017 adjusted ... 8 percent to $0.93 ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
Breaking Medicine Technology: